Gynaecological Screening for Cervical and Vulvar Malignancies in a Cohort of Systemic Sclerosis Patients: Our Experience and Review of the Literature

Table 1

Clinical features and pap test screening findings in 80 SSc patients.

	SSc series	Normal	Inflammation	Atypical cells/cancer	values
	()	A )	B ()	C ()	(A versus C)	(A + B versus C)
Age at onset	51.2 ± 12	51.2 ± 12	51.2 ± 12	65 (46–67)	0.052	0.06
SSc duration	7.9 ± 5.8	8 ± 5.8	8 ± 5.8	6 (1–13)	0.45	0.45
Skin subsets
Limited	72 (90%)	50 (90.9%)	18 (90%)	4 (80%)	0.42	0.42
Diffuse	8 (10%)	5 (9%)	2 (10%)	1 (20%)	0.42	0.42
Serology
Anti-Scl70	23 (28.7%)	17 (30.9%)	2 (10%)	4 (80%)	0.046	0.022
ACA	37 (46.2%)	28 (50.9%)	8 (40%)	1 (20%)	0.35	0.37
ANoA	14 (17.5%)	6 (10.9%)	8 (40%)	0	1	0.58
Digital ulcers	29 (36.2%)	21 (38.2%)	7 (35%)	1 (20%)	0.64	0.65
Interstitial lung disease	30 (37.5%)	22 (40%)	8 (40%)	0	0.15	0.15
FVC < 70%	4 (5%)	3 (5.4%)	0	1 (20%)	0.30	0.23
DLCO < 70%	46 (57.5%)	32 (58.2%)	12 (60%)	2 (40%)	0.65	0.65
PAH	0
History of smoking	27 (33.7%)	16 (29.1%)	9 (45%)	2 (40%)	0.63	1
History of immunosuppressant	5 (6.2%)	4 (7.3%)	1 (5%)	0	1	1
Pap test
Negative	55 (68.7%)
Inflammatory alterations	20 (25%)
Atypical cells/cancer	5 (6.2%)